Akèy › Sakom Sinovyol
Etid klinik pou Sakom Sinovyol ap rekrite nan Etazini
13 etid pou Sakom Sinovyol ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
- Illinois4 etid
- Kalifòni5 etid
- Massachusetts5 etid
- Missouri3 etid
- New York3 etid
- Pennsylvania3 etid
- Texas4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06644755Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05711615N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
Ap rekriteFaz 1 bonè
Laj 18 a 80 · Tout sèks · Mizajou Aug 27, 2026 · NCT07261657SPEARHEAD-3 Pediatric Study
Ap rekriteFaz 1/2
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Ap rekriteFaz 1
Laj 16 a 80 · Tout sèks · Mizajou Jul 29, 2026 · NCT06083883AOH1996 for the Treatment of Refractory Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT05227326Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Jun 30, 2026 · NCT06625190XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06571734Synovial Sarcoma Registry / Biospecimen Repository
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 9, 2026 · NCT05910307Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT03016819HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Jan 22, 2026 · NCT04995003ACTengine® IMA203 Combined With mRNA-4203
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT06946225Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.